Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.
Identifieur interne : 000232 ( PubMed/Checkpoint ); précédent : 000231; suivant : 000233Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.
Auteurs : Nigel J. Dimmock [Royaume-Uni] ; Edward W. Rainsford ; Paul D. Scott ; Anthony C. MarriottSource :
- Journal of virology [ 1098-5514 ] ; 2008.
Descripteurs français
- KwdFr :
- ARN viral (analyse), ARN viral (usage thérapeutique), Animaux, Antiviraux (usage thérapeutique), Dose létale 50, Facteurs temps, Humains, Indice de gravité médicale, Infections à Orthomyxoviridae (), Lignée cellulaire, Perte de poids, Plasmides, Rein (cytologie), Souris, Souris de lignée C3H, Sous-type H1N1 du virus de la grippe A (physiologie), Sous-type H2N2 du virus de la grippe A (physiologie), Sous-type H3N2 du virus de la grippe A (physiologie), Sous-type H3N8 du virus de la grippe A (physiologie), Transfection, Virus assistants (physiologie), Virus de la grippe A (physiologie), Virus défectifs (physiologie).
- MESH :
- analyse : ARN viral.
- cytologie : Rein.
- physiologie : Sous-type H1N1 du virus de la grippe A, Sous-type H2N2 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Sous-type H3N8 du virus de la grippe A, Virus assistants, Virus de la grippe A, Virus défectifs.
- usage thérapeutique : ARN viral, Antiviraux.
- Animaux, Dose létale 50, Facteurs temps, Humains, Indice de gravité médicale, Infections à Orthomyxoviridae, Lignée cellulaire, Perte de poids, Plasmides, Souris, Souris de lignée C3H, Transfection.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Cell Line, Defective Viruses (physiology), Helper Viruses (physiology), Humans, Influenza A Virus, H1N1 Subtype (physiology), Influenza A Virus, H2N2 Subtype (physiology), Influenza A Virus, H3N2 Subtype (physiology), Influenza A Virus, H3N8 Subtype (physiology), Influenza A virus (physiology), Kidney (cytology), Lethal Dose 50, Mice, Mice, Inbred C3H, Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (therapy), Plasmids, RNA, Viral (analysis), RNA, Viral (therapeutic use), Severity of Illness Index, Time Factors, Transfection, Weight Loss.
- MESH :
- chemical , analysis : RNA, Viral.
- chemical , therapeutic use : Antiviral Agents, RNA, Viral.
- cytology : Kidney.
- physiology : Defective Viruses, Helper Viruses, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A Virus, H3N8 Subtype, Influenza A virus.
- prevention & control : Orthomyxoviridae Infections.
- therapy : Orthomyxoviridae Infections.
- Animals, Cell Line, Humans, Lethal Dose 50, Mice, Mice, Inbred C3H, Plasmids, Severity of Illness Index, Time Factors, Transfection, Weight Loss.
Abstract
Another influenza pandemic is inevitable, and new measures to combat this and seasonal influenza are urgently needed. Here we describe a new concept in antivirals based on a defined, naturally occurring defective influenza virus RNA that has the potential to protect against any influenza A virus in any animal host. This "protecting RNA" (244 RNA) is incorporated into virions which, although noninfectious, deliver the RNA to those cells of the respiratory tract that are naturally targeted by infectious influenza virus. A 120-ng intranasal dose of this 244 protecting virus completely protected mice against a simultaneous challenge of 10 50% lethal doses with influenza A/WSN (H1N1) virus. The 244 virus also protected mice against strong challenge doses of all other subtypes tested (i.e., H2N2, H3N2, and H3N8). This prophylactic activity was maintained in the animal for at least 1 week prior to challenge. The 244 virus was 10- to 100-fold more active than previously characterized defective influenza A viruses, and the protecting activity was confirmed to reside in the 244 RNA molecule by recovering a protecting virus entirely from cloned cDNA. There was a clear therapeutic benefit when the 244 virus was administered 24 to 48 h after a lethal challenge, an effect which has not been previously observed with any defective virus. Protecting virus reduced, but did not abolish, replication of challenge virus in mouse lungs during both prophylactic and therapeutic treatments. Protecting virus is a novel antiviral, having the potential to combat human influenza virus infections, particularly when the infecting strain is not known or is resistant to antiviral drugs.
DOI: 10.1128/JVI.00743-08
PubMed: 18579602
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18579602Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.</title><author><name sortKey="Dimmock, Nigel J" sort="Dimmock, Nigel J" uniqKey="Dimmock N" first="Nigel J" last="Dimmock">Nigel J. Dimmock</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, University of Warwick, Coventry, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biological Sciences, University of Warwick, Coventry</wicri:regionArea><wicri:noRegion>Coventry</wicri:noRegion></affiliation></author><author><name sortKey="Rainsford, Edward W" sort="Rainsford, Edward W" uniqKey="Rainsford E" first="Edward W" last="Rainsford">Edward W. Rainsford</name></author><author><name sortKey="Scott, Paul D" sort="Scott, Paul D" uniqKey="Scott P" first="Paul D" last="Scott">Paul D. Scott</name></author><author><name sortKey="Marriott, Anthony C" sort="Marriott, Anthony C" uniqKey="Marriott A" first="Anthony C" last="Marriott">Anthony C. Marriott</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18579602</idno><idno type="pmid">18579602</idno><idno type="doi">10.1128/JVI.00743-08</idno><idno type="wicri:Area/PubMed/Corpus">000257</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000257</idno><idno type="wicri:Area/PubMed/Curation">000257</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000257</idno><idno type="wicri:Area/PubMed/Checkpoint">000232</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000232</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.</title><author><name sortKey="Dimmock, Nigel J" sort="Dimmock, Nigel J" uniqKey="Dimmock N" first="Nigel J" last="Dimmock">Nigel J. Dimmock</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biological Sciences, University of Warwick, Coventry, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biological Sciences, University of Warwick, Coventry</wicri:regionArea><wicri:noRegion>Coventry</wicri:noRegion></affiliation></author><author><name sortKey="Rainsford, Edward W" sort="Rainsford, Edward W" uniqKey="Rainsford E" first="Edward W" last="Rainsford">Edward W. Rainsford</name></author><author><name sortKey="Scott, Paul D" sort="Scott, Paul D" uniqKey="Scott P" first="Paul D" last="Scott">Paul D. Scott</name></author><author><name sortKey="Marriott, Anthony C" sort="Marriott, Anthony C" uniqKey="Marriott A" first="Anthony C" last="Marriott">Anthony C. Marriott</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Cell Line</term><term>Defective Viruses (physiology)</term><term>Helper Viruses (physiology)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (physiology)</term><term>Influenza A Virus, H2N2 Subtype (physiology)</term><term>Influenza A Virus, H3N2 Subtype (physiology)</term><term>Influenza A Virus, H3N8 Subtype (physiology)</term><term>Influenza A virus (physiology)</term><term>Kidney (cytology)</term><term>Lethal Dose 50</term><term>Mice</term><term>Mice, Inbred C3H</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Orthomyxoviridae Infections (therapy)</term><term>Plasmids</term><term>RNA, Viral (analysis)</term><term>RNA, Viral (therapeutic use)</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Transfection</term><term>Weight Loss</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (analyse)</term><term>ARN viral (usage thérapeutique)</term><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Dose létale 50</term><term>Facteurs temps</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à Orthomyxoviridae ()</term><term>Lignée cellulaire</term><term>Perte de poids</term><term>Plasmides</term><term>Rein (cytologie)</term><term>Souris</term><term>Souris de lignée C3H</term><term>Sous-type H1N1 du virus de la grippe A (physiologie)</term><term>Sous-type H2N2 du virus de la grippe A (physiologie)</term><term>Sous-type H3N2 du virus de la grippe A (physiologie)</term><term>Sous-type H3N8 du virus de la grippe A (physiologie)</term><term>Transfection</term><term>Virus assistants (physiologie)</term><term>Virus de la grippe A (physiologie)</term><term>Virus défectifs (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Rein</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Kidney</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Sous-type H3N8 du virus de la grippe A</term><term>Virus assistants</term><term>Virus de la grippe A</term><term>Virus défectifs</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Defective Viruses</term><term>Helper Viruses</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A Virus, H3N8 Subtype</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>ARN viral</term><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Humans</term><term>Lethal Dose 50</term><term>Mice</term><term>Mice, Inbred C3H</term><term>Plasmids</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Transfection</term><term>Weight Loss</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Dose létale 50</term><term>Facteurs temps</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à Orthomyxoviridae</term><term>Lignée cellulaire</term><term>Perte de poids</term><term>Plasmides</term><term>Souris</term><term>Souris de lignée C3H</term><term>Transfection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Another influenza pandemic is inevitable, and new measures to combat this and seasonal influenza are urgently needed. Here we describe a new concept in antivirals based on a defined, naturally occurring defective influenza virus RNA that has the potential to protect against any influenza A virus in any animal host. This "protecting RNA" (244 RNA) is incorporated into virions which, although noninfectious, deliver the RNA to those cells of the respiratory tract that are naturally targeted by infectious influenza virus. A 120-ng intranasal dose of this 244 protecting virus completely protected mice against a simultaneous challenge of 10 50% lethal doses with influenza A/WSN (H1N1) virus. The 244 virus also protected mice against strong challenge doses of all other subtypes tested (i.e., H2N2, H3N2, and H3N8). This prophylactic activity was maintained in the animal for at least 1 week prior to challenge. The 244 virus was 10- to 100-fold more active than previously characterized defective influenza A viruses, and the protecting activity was confirmed to reside in the 244 RNA molecule by recovering a protecting virus entirely from cloned cDNA. There was a clear therapeutic benefit when the 244 virus was administered 24 to 48 h after a lethal challenge, an effect which has not been previously observed with any defective virus. Protecting virus reduced, but did not abolish, replication of challenge virus in mouse lungs during both prophylactic and therapeutic treatments. Protecting virus is a novel antiviral, having the potential to combat human influenza virus infections, particularly when the infecting strain is not known or is resistant to antiviral drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18579602</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>17</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.</ArticleTitle><Pagination><MedlinePgn>8570-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00743-08</ELocationID><Abstract><AbstractText>Another influenza pandemic is inevitable, and new measures to combat this and seasonal influenza are urgently needed. Here we describe a new concept in antivirals based on a defined, naturally occurring defective influenza virus RNA that has the potential to protect against any influenza A virus in any animal host. This "protecting RNA" (244 RNA) is incorporated into virions which, although noninfectious, deliver the RNA to those cells of the respiratory tract that are naturally targeted by infectious influenza virus. A 120-ng intranasal dose of this 244 protecting virus completely protected mice against a simultaneous challenge of 10 50% lethal doses with influenza A/WSN (H1N1) virus. The 244 virus also protected mice against strong challenge doses of all other subtypes tested (i.e., H2N2, H3N2, and H3N8). This prophylactic activity was maintained in the animal for at least 1 week prior to challenge. The 244 virus was 10- to 100-fold more active than previously characterized defective influenza A viruses, and the protecting activity was confirmed to reside in the 244 RNA molecule by recovering a protecting virus entirely from cloned cDNA. There was a clear therapeutic benefit when the 244 virus was administered 24 to 48 h after a lethal challenge, an effect which has not been previously observed with any defective virus. Protecting virus reduced, but did not abolish, replication of challenge virus in mouse lungs during both prophylactic and therapeutic treatments. Protecting virus is a novel antiviral, having the potential to combat human influenza virus infections, particularly when the infecting strain is not known or is resistant to antiviral drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dimmock</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, University of Warwick, Coventry, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainsford</LastName><ForeName>Edward W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>Anthony C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003673" MajorTopicYN="N">Defective Viruses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006378" MajorTopicYN="N">Helper Viruses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053123" MajorTopicYN="N">Influenza A Virus, H3N8 Subtype</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007928" MajorTopicYN="N">Lethal Dose 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="Y">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18579602</ArticleId><ArticleId IdType="pii">JVI.00743-08</ArticleId><ArticleId IdType="doi">10.1128/JVI.00743-08</ArticleId><ArticleId IdType="pmc">PMC2519629</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2005 Oct 20;437(7062):1108</Citation><ArticleIdList><ArticleId IdType="pubmed">16228009</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Jul 20;351(1):101-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16631220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jan 26;439(7075):490-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16437116</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2006 Jan 28;332(7535):196</Citation><ArticleIdList><ArticleId IdType="pubmed">16439387</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Feb 23;354(8):785-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16495389</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Mar 23;440(7083):435-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16554799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2006 May;87(Pt 5):1259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16603528</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Apr 21;312(5772):452-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16556799</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2000;51:407-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10774473</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2003 Jan 5;305(1):192-200</Citation><ArticleIdList><ArticleId IdType="pubmed">12504552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2003 Mar;108(1):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12565156</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2003;16(3):415-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14583155</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Microbiol. 2003 Dec 30;97(3-4):259-68</Citation><ArticleIdList><ArticleId IdType="pubmed">14654295</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Phytopathol. 2004;42:415-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15283672</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Aug 13;22(23-24):3018-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15297051</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2004 Oct 1;39(7):920-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15472840</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1970 Apr 25;226(5243):325-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5439728</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Rev. 1980 Jun;44(2):303-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6991901</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1982 Feb;117(1):280-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6175087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1983 Sep;34(2):619-27</Citation><ArticleIdList><ArticleId IdType="pubmed">6616623</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1987 Aug;159(2):259-64</Citation><ArticleIdList><ArticleId IdType="pubmed">3617499</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1990 Apr;175(2):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">2327072</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1990;111(3-4):263-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2353873</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1991 Jul;72 ( Pt 7):1695-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1677414</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Rev. 1992 Mar;56(1):152-79</Citation><ArticleIdList><ArticleId IdType="pubmed">1579108</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1994 Dec;75 ( Pt 12):3485-91</Citation><ArticleIdList><ArticleId IdType="pubmed">7996140</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 1996 Apr;150:23-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8782700</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1998 Sep 1;248(2):241-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9721233</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50</Citation><ArticleIdList><ArticleId IdType="pubmed">10430945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Oct 9;354(9186):1277-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10520648</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Oct 6;437(7060):889-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16208372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 May 15;24(20):4290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16621180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Nov 4;123(3):368-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16269328</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Marriott, Anthony C" sort="Marriott, Anthony C" uniqKey="Marriott A" first="Anthony C" last="Marriott">Anthony C. Marriott</name><name sortKey="Rainsford, Edward W" sort="Rainsford, Edward W" uniqKey="Rainsford E" first="Edward W" last="Rainsford">Edward W. Rainsford</name><name sortKey="Scott, Paul D" sort="Scott, Paul D" uniqKey="Scott P" first="Paul D" last="Scott">Paul D. Scott</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Dimmock, Nigel J" sort="Dimmock, Nigel J" uniqKey="Dimmock N" first="Nigel J" last="Dimmock">Nigel J. Dimmock</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000232 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000232 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18579602
|texte= Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18579602" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |